NovoCure Ltd
NVCRNasdaq
$15.92
↓ -3.0%Jul 17 close · end-of-day
Price
1Y↓ -4.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$1.7B
P/E
—
P/S
2.7
P/B
5.5
EV/EBITDA
—
PEG
—
FCF Yield
-2.6%
Dividend Yield
—
Revenue (TTM)
$674.4M
Net Income (TTM)
-$173.0M
Free Cash Flow (TTM)
-$48.1M
Gross Margin
75.2%
Operating Margin
-27.2%
Net Margin
-25.7%
ROE
-52.3%
ROIC
-59.6%
Debt / Equity
—
Net Cash
$87.5M
Return 1Y
-1.8%
Company profile
NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.
- CEO
- Asaf Danziger
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 1,320
- Website
- novocure.com
Management & directors
- Ben Arye BarakGeneral Counsel
- Leonard Frank XEVP, Pres., Novocure Oncology
- Puri Michal NathChief Human Resources Officer
- Paravasthu MukundChief Operating Officer
- Brackmann ChristophChief Financial Officer
- Cordova AshleyFormer Chief Executive Officer
- Leupin NicolasFormer Chief Medical Officer
- Weinberg UriChf Medical and Innovation Ofr
- Doyle William FExecutive Chairman
Roles derived from SEC Form 4 filings.
Earnings
NVCR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$174.1M↑ +12.3%
Diluted EPS-$0.62↑ +100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Gross profit | $387.9M | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Operating income | $30.4M | -$44.3M | -$89.5M | -$232.9M | -$170.5M | -$153.8M |
| Net income | $19.8M | -$58.0M | -$93.0M | -$207.0M | -$169.0M | -$136.2M |
| Diluted EPS | $0.18 | -$0.56 | -$0.88 | -$1.95 | -$1.56 | -$1.22 |
| Operating cash flow | $99.1M | $82.8M | $30.8M | -$73.3M | -$26.4M | -$49.0M |
| Free cash flow | $84.2M | $58.6M | $9.4M | -$100.4M | -$69.2M | -$75.7M |
| Gross margin | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating margin | 6.1% | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Net margin | 4.0% | -10.8% | -17.3% | -40.6% | -27.9% | -20.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150.4M | $155.1M | $161.3M | $155.0M | $158.8M | $167.2M | $174.3M | $174.1M |
| Gross profit | $115.7M | $119.7M | $127.8M | $116.5M | $117.3M | $122.5M | $132.2M | $135.1M |
| Operating income | -$33.6M | -$32.1M | -$63.3M | -$37.9M | -$39.5M | -$36.0M | -$40.4M | -$67.4M |
| Net income | -$33.4M | -$30.6M | -$66.3M | -$34.3M | -$40.1M | -$37.3M | -$24.5M | -$71.1M |
| Diluted EPS | -$0.31 | -$0.28 | -$0.61 | -$0.31 | -$0.36 | -$0.33 | -$0.22 | -$0.62 |
| Operating cash flow | -$1.7M | $10.4M | -$3.5M | -$35.7M | -$15.9M | $20.6M | -$18.0M | -$13.5M |
| Free cash flow | -$13.2M | -$307,000.00 | -$12.4M | -$46.3M | -$21.4M | $14.9M | -$22.9M | -$18.7M |
| Gross margin | 77.0% | 77.2% | 79.2% | 75.1% | 73.9% | 73.2% | 75.8% | 77.6% |
| Operating margin | -22.3% | -20.7% | -39.3% | -24.4% | -24.9% | -21.5% | -23.2% | -38.7% |
| Net margin | -22.2% | -19.7% | -41.1% | -22.1% | -25.3% | -22.3% | -14.1% | -40.9% |
Company news
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Leonard Frank X· Chief Executive Officer | Award | 1,905 | $11.15 | $21,240.75 | filing |
| 2026-06-30 | Puri Michal Nath· Chief Human Resources Officer | Award | 1,905 | $11.15 | $21,240.75 | filing |
| 2026-06-30 | Ben Arye Barak· General Counsel | Award | 1,299 | $11.15 | $14,483.85 | filing |
| 2026-06-30 | Danziger Asaf | Award | 268 | $11.15 | $2,988.20 | filing |
| 2026-06-04 | Leonard Frank X· Chief Executive Officer | Sale | 34,273 | $17.93 | $614,634.85 | filing |
| 2026-06-03 | LEUNG GABRIEL | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | Stafford Kristin | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | Ocean Allyson J | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | Scannell Timothy J | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | HILLEMAN JERYL L | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | Hung David | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | Madden Martin J. | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-03 | VERNON W ANTHONY | Award | 11,610 | $0.00 | $0.00 | filing |
| 2026-06-02 | Stafford Kristin | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | LEUNG GABRIEL | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | Ocean Allyson J | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | Scannell Timothy J | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | HILLEMAN JERYL L | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | VERNON W ANTHONY | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-06-02 | Hung David | Sale | 2,945 | $15.77 | $46,444.71 | filing |
| 2026-04-28 | VERNON W ANTHONY | Option exercise | 21,500 | $11.39 | $244,885.00 | filing |
| 2026-03-05 | Paravasthu Mukund· Chief Operating Officer | Sale | 43,246 | $13.77 | $595,670.40 | filing |
| 2026-03-04 | Cordova Ashley· Former Chief Executive Officer | Tax withholding | 17,638 | $13.30 | $234,585.40 | filing |
| 2026-03-04 | Weinberg Uri· Chf Medical and Innovation Ofr | Sale | 6,412 | $13.31 | $85,314.22 | filing |
| 2026-03-04 | Brackmann Christoph· Chief Financial Officer | Sale | 6,412 | $13.31 | $85,314.22 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.